Vycor Medical (VYCO) 10-Q 13 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - $ / shares	9 Months Ended
	Sep. 30, 2024	Nov. 13, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-34932
Entity Registrant Name	VYCOR MEDICAL, INC.
Entity Central Index Key	0001424768
Entity Tax Identification Number	20-3369218
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	951 Broken Sound Parkway
Entity Address, Address Line Two	Suite 320
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33487
City Area Code	(561)
Local Phone Number	558-2020
Title of 12(b) Security	Common Stock
Trading Symbol	VYCO
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		33,372,796
Entity Listing, Par Value Per Share	$ 0.0001

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current Assets
Cash	$ 157,633	$ 57,291
Trade accounts receivable	238,700	215,231
Inventory	187,627	234,145
Prepaid expenses and other current assets	158,500	76,684
Current assets of discontinued operations	970	739
Total Current Assets	743,430	584,090
Fixed assets, net	209,732	252,404
Intangible and Other assets:
Security deposits	6,000	6,000
Operating lease - right of use assets	115,442	149,804
Total Intangible and Other assets	121,442	155,804
TOTAL ASSETS	1,074,604	992,298
Current Liabilities
Accounts payable	150,980	117,801
Current operating lease liabilities	47,178	45,321
Current liabilities of discontinued operations	(672)	(1,100)
Total Current Liabilities	4,552,889	4,074,487
Operating lease liability - long term	64,745	100,379
Loan payable - SBA EIDL	140,316	142,908
Total Liabilities	4,757,950	4,317,774
STOCKHOLDERS’ DEFICIENCY
Common Stock, $0.0001 par value, 55,000,000 shares authorized at September 30, 2024 and December 31, 2023, 33,476,130 and 32,732,169 shares issued and 33,372,796 and 32,628,835 shares outstanding at September 30, 2024 and December 31, 2023 respectively	3,348	3,273
Additional Paid-in Capital	29,431,958	29,365,070
Treasury Stock (103,334 shares of Common Stock as at September 30, 2024 and December 31, 2023 respectively, at cost)	(1,033)	(1,033)
Accumulated Deficit	(33,245,323)	(32,820,490)
Accumulated Other Comprehensive Income	127,677	127,677
Total Stockholders’ Deficiency	(3,683,346)	(3,325,476)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY	1,074,604	992,298
Series C Preferred Stock [Member]
STOCKHOLDERS’ DEFICIENCY
Preferred Stock, Value
Series D Preferred Stock [Member]
STOCKHOLDERS’ DEFICIENCY
Preferred Stock, Value	27	27
Nonrelated Party [Member]
Current Liabilities
Accrued interest	508,931	472,897
Accrued liabilities - Other	187,995	151,816
Notes payable	337,179	328,267
Related Party [Member]
Current Liabilities
Accrued interest	232,965	195,522
Dividends payable - Related Party	2,594,960	2,270,590
Notes payable	$ 493,373	$ 493,373

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	55,000,000	55,000,000
Common stock, shares issued	33,476,130	32,732,169
Common stock, shares outstanding	33,372,796	32,628,835
Treasury stock, common shares	103,334	103,334
Series C Preferred Stock [Member]
Preferred stock, shares issued	1	1
Preferred stock, shares oustanding	1	1
Series D Preferred Stock [Member]
Preferred stock, shares issued	270,306	270,306
Preferred stock, shares oustanding	270,306	270,306

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Defined Benefit Plan Disclosure [Line Items]
Revenue	$ 390,852	$ 308,593	$ 1,134,098	$ 1,152,355
Cost of Goods Sold	36,796	32,334	108,965	102,930
Gross Profit	354,056	276,259	1,025,133	1,049,425
Operating Expenses:
Research and development	6,425	7,250	8,688	20,308
Depreciation and amortization	14,880	14,377	44,641	43,126
Selling, general and administrative	367,886	280,113	1,000,293	881,744
Total Operating Expenses	389,191	301,740	1,053,622	945,178
Operating income (loss)	(35,135)	(25,481)	(28,489)	104,247
Other Income (Expense)
Other Income	1,458		6,002
Loss on foreign currency exchange	(103)	(78)	(252)	(209)
Total Other Income (Expense)	(24,635)	(25,998)	(71,777)	(77,366)
Income (Loss) Before Provision for Income Taxes	(59,770)	(51,479)	(100,266)	26,881
Provision for income taxes
Net Income (Loss) from continuing operations	(59,770)	(51,479)	(100,266)	26,881
Loss from discontinued operations, net of tax	(47)	(425)	(197)	(3,517)
Net Income (Loss)	(59,817)	(51,904)	(100,463)	23,364
Preferred stock dividends	(162,185)	(162,185)	(324,370)	(324,370)
Net Loss Available to Common Stockholders	(222,002)	(214,089)	(424,833)	(301,006)
Other Comprehensive Income (Loss)
Foreign Currency Translation Adjustment				2
Comprehensive Income (Loss)	$ (59,817)	$ (51,904)	$ (100,463)	$ 23,366
Loss Per Share - basic and diluted
Net Income (Loss) from continuing operations - basic	$ (0.01)	$ (0.01)	$ (0.01)	$ (0.01)
Net Income (Loss) from continuing operations - diluted	(0.01)	(0.01)	(0.01)	(0.01)
Loss from discontinued operations - basic	0	0	0	0
Loss from discontinued operations - diluted	0	0	0	0
Net Income (Loss) available to common stockholders - basic	(0.01)	(0.01)	(0.01)	(0.01)
Net Income (Loss) available to common stockholders - diluted	$ (0.01)	$ (0.01)	$ (0.01)	$ (0.01)
Weighted Average Number of Shares Outstanding – Basic and Diluted	32,903,493	32,628,835	32,721,056	32,595,320
Related Party [Member]
Other Income (Expense)
Interest expense	$ (12,571)	$ (12,436)	$ (37,443)	$ (37,080)
Nonrelated Party [Member]
Other Income (Expense)
Interest expense	$ (13,419)	$ (13,484)	$ (40,084)	$ (40,077)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Balance	$ (3,528,307)	$ (3,018,332)	$ (3,325,476)	$ (2,940,871)
Issuance of stock for board and consulting fees	73,257		73,257	9,454
Repurchase and cancellation of stock	(6,294)		(6,294)
Net income for nine months ended September 30, 2023	(59,817)	(51,904)	(100,463)	23,364
Preferred Stock dividends	(162,185)	(162,185)	(324,370)	(324,370)
Balance	(3,683,346)	(3,232,421)	(3,683,346)	(3,232,421)
Foreign currency translation adjustment				2
Common Stock [Member]
Balance	$ 3,273	$ 3,273	$ 3,273	$ 3,263
Balance, shares	32,732,169	32,732,169	32,732,169	32,630,506
Issuance of stock for board and consulting fees	$ 82		$ 82	$ 10
Issuance/Buyback of stock for board and consulting fees, shares	813,971		813,971	101,663
Repurchase and cancellation of stock	$ (7)		$ (7)
Repurchase and cancellation of stock, shares	(70,010)		(70,010)
Net income for nine months ended September 30, 2023
Balance	$ 3,348	$ 3,273	$ 3,348	$ 3,273
Balance, shares	33,476,130	32,732,169	33,476,130	32,732,169
Preferred Stock [Member] | Series C Preferred Stock [Member]
Balance	$ 0	$ 0	$ 0	$ 0
Balance, shares	1	1	1	1
Net income for nine months ended September 30, 2023
Balance	$ 0	$ 0	$ 0	$ 0
Balance, shares	1	1	1	1
Preferred Stock [Member] | Series D Preferred Stock [Member]
Balance	$ 27	$ 27	$ 27	$ 27
Balance, shares	270,306	270,306	270,306	270,306
Net income for nine months ended September 30, 2023
Balance	$ 27	$ 27	$ 27	$ 27
Balance, shares	270,306	270,306	270,306	270,306
Treasury Stock, Common [Member]
Balance	$ (1,033)	$ (1,033)	$ (1,033)	$ (1,033)
Balance, shares	(103,334)	(103,334)	(103,334)	(103,334)
Net income for nine months ended September 30, 2023
Balance	$ (1,033)	$ (1,033)	$ (1,033)	$ (1,033)
Balance, shares	(103,334)	(103,334)	(103,334)	(103,334)
Additional Paid-in Capital [Member]
Balance	$ 29,365,070	$ 29,365,070	$ 29,365,070	$ 29,355,626
Issuance of stock for board and consulting fees	73,175		73,175	9,444
Repurchase and cancellation of stock	(6,287)		(6,287)
Net income for nine months ended September 30, 2023
Balance	29,431,958	29,365,070	29,431,958	29,365,070
Retained Earnings [Member]
Balance	(33,023,321)	(32,513,346)	(32,820,490)	(32,426,429)
Net income for nine months ended September 30, 2023	(59,817)	(51,904)	(100,463)	23,364
Preferred Stock dividends	(162,185)	(162,185)	(324,370)	(324,370)
Balance	(33,245,323)	(32,727,435)	(33,245,323)	(32,727,435)
AOCI Attributable to Parent [Member]
Balance	127,677	127,677	127,677	127,675
Net income for nine months ended September 30, 2023
Balance	$ 127,677	$ 127,677	$ 127,677	127,677
Foreign currency translation adjustment				$ 2

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net income (loss)	$ (100,463)	$ 23,364
Adjustments to reconcile net income (loss) to cash provided by operating activities:
Depreciation of fixed assets	47,041	45,650
Allowance for doubtful accounts – accounts receivable	3,375
Stock based compensation	8,469	7,777
Changes in operating assets and liabilities:
Accounts receivable	(26,844)	(99,062)
Inventory	46,518	44,135
Prepaid expenses	(22,737)	(15,519)
Accrued interest - Related Party	37,443	37,080
Accrued interest - Other	36,034	35,901
Accounts payable	33,179	(86,315)
Accrued liabilities - Other	36,179	29,996
Changes in discontinued operations, net	197	915
Cash provided by operating activities	98,391	23,922
Cash flows from investing activities:
Purchase of fixed assets net of sales	(4,369)	(3,482)
Cash used by investing activities	(4,369)	(3,482)
Cash flows from financing activities:
Proceeds - Notes Payable Other	60,980	64,786
Repayments - Notes Payable Other	(54,660)	(53,208)
Cash provided by financing activities	6,320	11,578
Effect of exchange rate changes on cash		2
Net increase in cash	100,342	32,020
Cash at beginning of period	57,291	37,035
Cash at end of period	157,633	69,055
Supplemental Disclosures of Cash Flow information:
Cash paid for interest	4,050	4,176
Cash paid for income tax
Non-Cash Activities
Non-cash accrued dividends	324,370	324,370
Unamortized stock compensation	$ 67,152	$ 4,727

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	1. BASIS OF PRESENTATION The accompanying unaudited consolidated financial statements of Vycor Medical, Inc. (the “Company” or “Vycor”) have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in consolidated financial statements have been omitted pursuant to such rules and regulations. The consolidated balance sheet as of December 31, 2023 derives from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These unaudited consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. The unaudited consolidated financial statements as of and for the three and nine months ended September 30, 2024 and 2023, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition, results of operations and cash flows. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Ability to continue as a Going Concern The accompanying unaudited consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred losses since its inception, including a net loss of $ 100,463 3,809,459 3,321,298 The Company is executing on a plan to achieve a reduction in cash operating losses. Included within the working capital deficiency above is a term note for $ 300,000 508,931 March 31, 2025

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	2. SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The unaudited consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company account balances, transactions, and profits have been eliminated in consolidation. Following the decision in April 2020 to close the German office of NovaVision, the activities of NovaVision GmbH have been accounted for as discontinued operations. Recent Accounting Pronouncements From time-to-time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The FASB issued Accounting Standards Update (ASU) 2023-07 in November 2023, effective for fiscal years beginning after December 15, 2023. The ASU is designed to improve reportable segment disclosures. Management has assessed the ASU and has concluded that it does not have an impact on its accounting or reporting, as the additional disclosure effects items that are not applied at a segment level. The Company believes that other recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented. Accounting for Share Repurchases During the nine months ended September 30, 2024 the Company repurchased shares from a single shareholder. The Company followed guidance ASC 505-30-30, retiring the stock and reducing Equity by the nominal value of the shares repurchased and reducing Additional Paid In Capital by the balance of the consideration paid. Revenue Recognition On January 1, 2018, the Company adopted, ASC 606, Revenue from Contracts with Customers and all the related amendments (new revenue standard) to all contracts. Vycor Medical generates revenue from the sale of its surgical access system to hospitals and other medical professionals. Vycor Medical records revenue from product sales when obligations under the terms of a contract with customers are satisfied. Generally, this occurs with the transfer of control of the goods to customers. Vycor Medical does not provide for product returns or warranty costs. Vycor determines revenue recognition through the following steps: ● Identification of the contract, or contracts, with a customer ● Identification of the performance obligations in the contract ● Determination of the transaction price ● Allocation of the transaction price to the performance obligations in the contract ● Recognition of revenue when Vycor satisfy a performance obligation NovaVision generates revenues from various programs, therapy services and other sources such as software license sales. Therapy services revenues represent fees from NovaVision’s vision restoration therapy software, eye movement training software, diagnostic software, clinic set up and training fees, and the professional and support services associated with the therapy. NovaVision provides vision restoration therapy directly to patients. The typical therapy program consists of NeuroEyeCoach, performed over 2-4 weeks, and six modules of Vision Restoration Therapy, performed over 6 months. A patient contract comprises set-up fees and monthly therapy fees. Set-up fees are recognized at the outset of the contract and therapy revenue is recognized ratably over the therapy period. Patient therapy is restricted to being completed by a patient within a specified time frame. Deferred revenue results from patients paying for the therapy in advance of receiving the therapy. The Company disaggregates its revenue by division – Vycor and NovaVision – and by geography – United States and Europe – and presents the disaggregation in Note 7. Net Income (Loss) Per Share Basic net income (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to increase a net income per share or reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented of net loss because the assumed conversion of preferred stock and debt would be anti-dilutive. The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share where a net loss is reported: SCHEDULE OF COMMON STOCK NOT INCLUDED IN CALCULATION OF DILUTED NET LOSS PER SHARE September 30, 2024 September 30, 2023 Debentures convertible into common stock 3,852,052 3,622,848 Preferred shares convertible into common stock 1,272,052 1,272,052 Total 5,124,104 4,894,900 Anti-dilutive shares 5,124,104 4,894,900 Reclassifications Certain prior period amounts have been reclassified to conform with the current period presentation; on the cash flow statement, proceeds from and repayments of insurance financing has been separated out rather than being netted off; on the statements of stockholders’ deficiency, net income (loss) for the period and preferred stock dividends have been separated out rather than being combined.

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	9 Months Ended
	Sep. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS	3. DISCONTINUED OPERATIONS In April 2020, the board of Vycor took the decision to close the German operations of NovaVision, including the German office and NovaVision GmbH, and instead migrate to a licensed business model; effective July 1, 2020, Vycor entered into a license agreement with a German-based partner. The NovaVision German office was closed effective June 30, 2020. The Company will continue to fund the remaining expenses of the German operations, which are non-material, until such a time as NovaVision GmbH will be formally wound up. Reconciliation of the major line items from discontinued operations that are presented in the unaudited consolidated balance sheets and unaudited consolidated statements of comprehensive income (loss) are as follows: SCHEDULE OF DISCONTINUED OPERATIONS Major line items constituting assets and liabilities in the unaudited consolidated balance sheets September 30, December 31, 2024 2023 ASSETS Current Assets Cash $ 970 $ 739 Total Current Assets 970 739 TOTAL ASSETS $ 970 $ 739 LIABILITIES Current Liabilities Accounts payable $ 4 $ 4 Other current liabilities (676 ) (1,104 ) Total Current Liabilities $ (672 ) $ (1,100 ) Major line items constituting loss from discontinued operations 2024 2023 2024 2023 For the three months ended September 30, For the nine months ended September 30, 2024 2023 2024 2023 Revenue $ - $ - $ - $ - Cost of Goods Sold - - - - Gross Profit - - - - Operating Expenses: Selling, general and administrative 47 425 197 3,365 Total Operating Expenses (47 ) (425 ) (197 ) (3,365 ) Operating Loss (47 ) (425 ) (197 ) (3,365 ) Other Income (Expense) Loss on foreign currency exchange - - - (152 ) Total Other Income (Expense) - - - (152 ) Loss Before Provision for Income Taxes (47 ) (425 ) (197 ) (3,517 ) Provision for income taxes - - - - Loss from discontinued operations, net of tax $ (47 ) $ (425 ) $ (197 ) $ (3,517 )

NOTES PAYABLE

NOTES PAYABLE	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
NOTES PAYABLE	4. NOTES PAYABLE Related Parties Notes Payable Related Party Notes Payable consists of: SUMMARY OF NOTES PAYABLE September 30, 2024 December 31, 2023 On June 25, 2018 the Company issued promissory notes to Peter Zachariou for $ 30,000 10 The note was extended for another twelve months on its due date to June 25, 2025 or on demand by the Payee. $ 30,000 $ 30,000 Between March 26, 2018 and November 17, 2022 the Company issued fifteen promissory notes to Fountainhead Capital Management Limited for $ 463,373 10 The Notes will be due between December 2024 and November 2025 or on demand by the Payee. 463,373 463,373 Total Related Party Notes Payable $ 493,373 $ 493,373 Other Notes Payable Other Notes Payable consists of: September 30, 2024 December 31, 2023 On March 25, 2011 the Company issued a term note for $ 300,000 16 March 31, 2025 $ 300,000 $ 300,000 Insurance policy finance agreements and current portion of EIDL Loan (see Long-Term Notes Payable below) 37,179 28,267 Total Other Notes Payable: $ 337,179 $ 328,267 Long-Term Notes Payable consists of: September 30, 2024 December 31, 2023 On July 7, 2020, the Company was granted a $ 150,000 30 3.75 731.00 $ 140,316 $ 142,908 Total Long-term Notes Payable: $ 140,316 $ 142,908 In January 2018 the Company entered into an amendment agreement (the “Amendment”) with EuroAmerican Investments (“EuroAmerican”) regarding its $ 300,000 0.21 3,852,052 The Company routinely finances all their insurance policies through a third-party finance company which requires a down payment and subsequent monthly payments, the time periods vary from 10 months to 12 equal monthly payments.

INVENTORY

INVENTORY	9 Months Ended
	Sep. 30, 2024
Inventory Disclosure [Abstract]
INVENTORY	5. INVENTORY SCHEDULE OF INVENTORY September 30, 2024 December 31, 2023 Raw materials and work in process $ 79,319 $ 88,236 Finished goods 108,308 145,909 Total Inventory $ 187,627 $ 234,145

LEASE

LEASE	9 Months Ended
	Sep. 30, 2024
Lease
LEASE	6. LEASE The Company recognized the following related to a lease in its unaudited consolidated balance sheets at September 30, 2024 and December 31, 2023: SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES September 30, 2024 December 31, 2023 Operating Lease ROU Assets $ 115,442 $ 149,804 Operating Lease Liabilities Current portion $ 47,178 $ 45,321 Long-term portion 64,745 100,379 Operating Lease Liabilities Total $ 111,923 $ 145,700

SEGMENT REPORTING, GEOGRAPHICAL

SEGMENT REPORTING, GEOGRAPHICAL INFORMATION	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
SEGMENT REPORTING, GEOGRAPHICAL INFORMATION	7. SEGMENT REPORTING, GEOGRAPHICAL INFORMATION (a) Business segments The Company operates in two SCHEDULE OF BUSINESS SEGMENTS INFORMATION 2024 2023 2024 2023 For the three months ended September 30, For the nine months ended September 30, 2024 2023 2024 2023 Revenue: Vycor Medical $ 372,837 $ 287,559 $ 1,078,644 $ 1,087,758 NovaVision 18,015 21,034 55,454 64,597 Revenue $ 390,852 $ 308,593 $ 1,134,098 $ 1,152,355 Gross Profit Vycor Medical $ 337,404 $ 256,435 $ 973,443 $ 989,288 NovaVision 16,652 19,824 51,690 60,137 Gross Profit $ 354,056 $ 276,259 $ 1,025,133 $ 1,049,425 Operating Income (Loss) Vycor Medical $ 52,688 $ 60,373 $ 223,061 $ 366,360 NovaVision (43,215 ) (41,868 ) (127,783 ) (146,592 ) Corporate (44,608 ) (43,986 ) (123,767 ) (115,521 ) Operating Income (Loss) $ (35,135 ) $ (25,481 ) $ (28,489 ) $ 104,247 September 30, December 31, 2024 2023 Total Assets: Vycor Medical $ 1,028,839 $ 957,936 NovaVision 44,795 33,623 Discontinued operations 970 739 Total Assets $ 1,074,604 $ 992,298 (b) Geographic segments The Company operates in two SUMMARY OF GEOGRAPHIC INFORMATION 2024 2023 2024 2023 For the three months ended September 30, For the nine months ended September 30, 2024 2023 2024 2023 Revenue: United States $ 389,477 $ 306,929 $ 1,131,150 $ 1,147,054 Europe 1,375 1,664 2,948 5,301 Revenue $ 390,852 $ 308,593 $ 1,134,098 $ 1,152,355 Gross Profit United States $ 352,720 $ 274,620 $ 1,022,224 $ 1,044,223 Europe 1,336 1,639 2,909 5,202 Gross Profit $ 354,056 $ 276,259 $ 1,025,133 $ 1,049,425 Operating Income (Loss) United States $ 15,312 $ 24,228 $ 113,166 $ 234,609 Europe (5,839 ) (5,723 ) (17,888 ) (14,841 ) Corporate (44,608 ) (43,986 ) (123,767 ) (115,521 ) Operating Income (Loss) $ (35,135 ) $ (25,481 ) $ (28,489 ) $ 104,247 September 30, December 31, 2024 2023 Total Assets: United States $ 1,064,821 $ 985,718 Europe 8,813 5,841 Discontinued operations 970 739 Total Assets $ 1,074,604 $ 992,298

EQUITY

EQUITY	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
EQUITY	8. EQUITY Equity Transactions On August 16, 2024 pursuant to a Share Purchase Agreement, Vycor repurchased and cancelled 70,010 6,294 On August 27, 2024 Vycor issued 813,971 73,257 6,105 During each of the three and nine months ended September 30, 2024 and 2023, the Company accrued $ 162,185 324,370 On April 1, 2023 the Company issued 101,663 Equity Classes Our authorized capital stock consists of 55,000,000 0.0001 10,000,000 0.0001 33,372,796 1 270,306 Holders of our common stock are entitled to one vote for each share on all matters voted upon by our stockholders, including the election of directors, and do not have cumulative voting rights. Subject to the rights of holders of any then outstanding shares of our preferred stock, our common stockholders are entitled to any dividends that may be declared by our board. Holders of our common stock are entitled to share ratably in our net assets upon our dissolution or liquidation after payment or provision for all liabilities and any preferential liquidation rights of our preferred stock then outstanding. Holders of our common stock have no preemptive rights to purchase shares of our stock. The shares of our common stock are not subject to any redemption provisions and are not convertible into any other shares of our capital stock. All outstanding shares of our common stock are, and the shares of common stock to be issued in the offering will be, upon payment therefor, fully paid and non-assessable. The rights, preferences and privileges of holders of our common stock will be subject to those of the holders of any shares of our preferred stock we may issue in the future. Preferred C Stock shares are convertible (at the Holder’s option or mandatorily upon the occurrence of certain events) into 14,815 3.75 Preferred D Stock shares are convertible into Company Common Shares at a price of $ 2.15 12

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	9. STOCK-BASED COMPENSATION The Company from time-to-time issues common stock, stock options or common stock warrants to acquire services or goods from non-employees. Common stock, stock options and common stock warrants issued to other than employees or directors are recorded on the basis of their fair value, which is measured as of the “measurement date” using an option pricing model, or their contractual value if different in the case of common stock. The “measurement date” for options and warrants related to contracts that have substantial disincentives to non-performance is the date of the contract, and for all other contracts is the vesting date. Expense related to the options and warrants is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. Non-Employee Stock Compensation Aggregate stock-based compensation for shares of common stock granted to non-employees for each of the nine months ended September 30, 2024 and 2023 was $ 8,469 7,777 6,105 2,363 67,152 2,364

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	10. COMMITMENTS AND CONTINGENCIES Lease The Company leases office space located at 951 Broken Sound Parkway, Suite 320, Boca Raton, FL 33487 from WPT Land 2 L.P., for a gross rent of approximately $ 4,300 2,700 August 31, 2023 three years and four months 62,856 53,535 20,535 16,362 Potential German tax liability In June 2012 the Company’s NovaVision German subsidiary received a preliminary assessment for Magdeburg City trade tax of € 75,000 82,000 12,000 13,200 75,000 82,000 12,000 13,200

CONSULTING AND OTHER AGREEMENTS

CONSULTING AND OTHER AGREEMENTS	9 Months Ended
	Sep. 30, 2024
Consulting And Other Agreements
CONSULTING AND OTHER AGREEMENTS	11. CONSULTING AND OTHER AGREEMENTS The following agreements were entered into or remained in force during the periods ended September 30, 2024 and 2023: On August 27, 2024 Vycor entered into a financial advisory and investment banking services agreement (“Agreement”) with Maxim. Under the terms of the Agreement, Maxim will assist Vycor in its strategy to grow the Company through strategic acquisitions and assist the Company with efforts to position itself for a potential uplisting to a US exchange. Vycor issued 813,971 73,257 On March 30, 2021, Vycor entered into a Consulting Agreement with Ricardo J. Komotar, M.D. (the “Agreement”) to provide certain specified services over the three-year term of the Agreement. On April 1, 2023, 101,663 9,455 0 2,364 2,363 7,777

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	12. RELATED PARTY TRANSACTIONS Peter Zachariou and David Cantor, directors of the Company, are investment managers of Fountainhead which owned, at September 30, 2024, 60.9 69.7 0.15 25.7 During each of the nine months ended September 30, 2024 and 2023, the Company accrued an aggregate of $ 324,370 226,037 83,386 2,594,960 2,270,590 1,808,297 1,582,260 667,087 583,701 During the nine months ended September 30, 2024 and 2023 the Company accrued interest on related party loans of $ 37,443 37,080 During the three months ended September 30, 2024 and 2023 the Company accrued interest on related party loans of $ 12,571 12,436

CONCENTRATION

CONCENTRATION	9 Months Ended
	Sep. 30, 2024
Risks and Uncertainties [Abstract]
CONCENTRATION	13. CONCENTRATION Vycor Medical sells its neurosurgical devices in the US primarily direct to hospitals, and internationally through distributors who in turn sell to hospitals. SCHEDULE OF CONCENTRATION Sales Concentration: For the three months For the nine months 2024 2023 2024 2023 Number of customers over 10% 0 1 0 1 Percentage of sales 0 % 16 % 0 % 12 % Accounts Receivable Concentration At September 30, 2024 At December 31, 2023 Number of customers over 10% - - Percentage of accounts receivable - % - % The Company has three sub-contract manufacturers from which it purchases, respectively, VBAS injection molded parts, completed and sterilized VBAS units, and extension arms. Purchases from these manufacturers vary from quarter to quarter, with no purchases in some quarters, however on an annual basis, purchases from each manufacturer represent over 10

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	14. SUBSEQUENT EVENTS The Company has evaluated the existence of events and transactions subsequent to the balance sheet date through the date the unaudited consolidated financial statements were issued and has determined that there were no significant subsequent events or transactions that would require recognition or disclosure in the financial statements.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The unaudited consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company account balances, transactions, and profits have been eliminated in consolidation. Following the decision in April 2020 to close the German office of NovaVision, the activities of NovaVision GmbH have been accounted for as discontinued operations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time-to-time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The FASB issued Accounting Standards Update (ASU) 2023-07 in November 2023, effective for fiscal years beginning after December 15, 2023. The ASU is designed to improve reportable segment disclosures. Management has assessed the ASU and has concluded that it does not have an impact on its accounting or reporting, as the additional disclosure effects items that are not applied at a segment level. The Company believes that other recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.
Accounting for Share Repurchases	Accounting for Share Repurchases During the nine months ended September 30, 2024 the Company repurchased shares from a single shareholder. The Company followed guidance ASC 505-30-30, retiring the stock and reducing Equity by the nominal value of the shares repurchased and reducing Additional Paid In Capital by the balance of the consideration paid.
Revenue Recognition	Revenue Recognition On January 1, 2018, the Company adopted, ASC 606, Revenue from Contracts with Customers and all the related amendments (new revenue standard) to all contracts. Vycor Medical generates revenue from the sale of its surgical access system to hospitals and other medical professionals. Vycor Medical records revenue from product sales when obligations under the terms of a contract with customers are satisfied. Generally, this occurs with the transfer of control of the goods to customers. Vycor Medical does not provide for product returns or warranty costs. Vycor determines revenue recognition through the following steps: ● Identification of the contract, or contracts, with a customer ● Identification of the performance obligations in the contract ● Determination of the transaction price ● Allocation of the transaction price to the performance obligations in the contract ● Recognition of revenue when Vycor satisfy a performance obligation NovaVision generates revenues from various programs, therapy services and other sources such as software license sales. Therapy services revenues represent fees from NovaVision’s vision restoration therapy software, eye movement training software, diagnostic software, clinic set up and training fees, and the professional and support services associated with the therapy. NovaVision provides vision restoration therapy directly to patients. The typical therapy program consists of NeuroEyeCoach, performed over 2-4 weeks, and six modules of Vision Restoration Therapy, performed over 6 months. A patient contract comprises set-up fees and monthly therapy fees. Set-up fees are recognized at the outset of the contract and therapy revenue is recognized ratably over the therapy period. Patient therapy is restricted to being completed by a patient within a specified time frame. Deferred revenue results from patients paying for the therapy in advance of receiving the therapy. The Company disaggregates its revenue by division – Vycor and NovaVision – and by geography – United States and Europe – and presents the disaggregation in Note 7.
Net Income (Loss) Per Share	Net Income (Loss) Per Share Basic net income (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to increase a net income per share or reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented of net loss because the assumed conversion of preferred stock and debt would be anti-dilutive. The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share where a net loss is reported: SCHEDULE OF COMMON STOCK NOT INCLUDED IN CALCULATION OF DILUTED NET LOSS PER SHARE September 30, 2024 September 30, 2023 Debentures convertible into common stock 3,852,052 3,622,848 Preferred shares convertible into common stock 1,272,052 1,272,052 Total 5,124,104 4,894,900 Anti-dilutive shares 5,124,104 4,894,900
Reclassifications	Reclassifications Certain prior period amounts have been reclassified to conform with the current period presentation; on the cash flow statement, proceeds from and repayments of insurance financing has been separated out rather than being netted off; on the statements of stockholders’ deficiency, net income (loss) for the period and preferred stock dividends have been separated out rather than being combined.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
SCHEDULE OF COMMON STOCK NOT INCLUDED IN CALCULATION OF DILUTED NET LOSS PER SHARE	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share where a net loss is reported: SCHEDULE OF COMMON STOCK NOT INCLUDED IN CALCULATION OF DILUTED NET LOSS PER SHARE September 30, 2024 September 30, 2023 Debentures convertible into common stock 3,852,052 3,622,848 Preferred shares convertible into common stock 1,272,052 1,272,052 Total 5,124,104 4,894,900 Anti-dilutive shares 5,124,104 4,894,900

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	9 Months Ended
	Sep. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
SCHEDULE OF DISCONTINUED OPERATIONS	Reconciliation of the major line items from discontinued operations that are presented in the unaudited consolidated balance sheets and unaudited consolidated statements of comprehensive income (loss) are as follows: SCHEDULE OF DISCONTINUED OPERATIONS Major line items constituting assets and liabilities in the unaudited consolidated balance sheets September 30, December 31, 2024 2023 ASSETS Current Assets Cash $ 970 $ 739 Total Current Assets 970 739 TOTAL ASSETS $ 970 $ 739 LIABILITIES Current Liabilities Accounts payable $ 4 $ 4 Other current liabilities (676 ) (1,104 ) Total Current Liabilities $ (672 ) $ (1,100 ) Major line items constituting loss from discontinued operations 2024 2023 2024 2023 For the three months ended September 30, For the nine months ended September 30, 2024 2023 2024 2023 Revenue $ - $ - $ - $ - Cost of Goods Sold - - - - Gross Profit - - - - Operating Expenses: Selling, general and administrative 47 425 197 3,365 Total Operating Expenses (47 ) (425 ) (197 ) (3,365 ) Operating Loss (47 ) (425 ) (197 ) (3,365 ) Other Income (Expense) Loss on foreign currency exchange - - - (152 ) Total Other Income (Expense) - - - (152 ) Loss Before Provision for Income Taxes (47 ) (425 ) (197 ) (3,517 ) Provision for income taxes - - - - Loss from discontinued operations, net of tax $ (47 ) $ (425 ) $ (197 ) $ (3,517 )

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
SUMMARY OF NOTES PAYABLE	Related Party Notes Payable consists of: SUMMARY OF NOTES PAYABLE September 30, 2024 December 31, 2023 On June 25, 2018 the Company issued promissory notes to Peter Zachariou for $ 30,000 10 The note was extended for another twelve months on its due date to June 25, 2025 or on demand by the Payee. $ 30,000 $ 30,000 Between March 26, 2018 and November 17, 2022 the Company issued fifteen promissory notes to Fountainhead Capital Management Limited for $ 463,373 10 The Notes will be due between December 2024 and November 2025 or on demand by the Payee. 463,373 463,373 Total Related Party Notes Payable $ 493,373 $ 493,373 Other Notes Payable Other Notes Payable consists of: September 30, 2024 December 31, 2023 On March 25, 2011 the Company issued a term note for $ 300,000 16 March 31, 2025 $ 300,000 $ 300,000 Insurance policy finance agreements and current portion of EIDL Loan (see Long-Term Notes Payable below) 37,179 28,267 Total Other Notes Payable: $ 337,179 $ 328,267 Long-Term Notes Payable consists of: September 30, 2024 December 31, 2023 On July 7, 2020, the Company was granted a $ 150,000 30 3.75 731.00 $ 140,316 $ 142,908 Total Long-term Notes Payable: $ 140,316 $ 142,908

INVENTORY (Tables)

INVENTORY (Tables)	9 Months Ended
	Sep. 30, 2024
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORY	SCHEDULE OF INVENTORY September 30, 2024 December 31, 2023 Raw materials and work in process $ 79,319 $ 88,236 Finished goods 108,308 145,909 Total Inventory $ 187,627 $ 234,145

LEASE (Tables)

LEASE (Tables)	9 Months Ended
	Sep. 30, 2024
Lease
SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES	The Company recognized the following related to a lease in its unaudited consolidated balance sheets at September 30, 2024 and December 31, 2023: SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES September 30, 2024 December 31, 2023 Operating Lease ROU Assets $ 115,442 $ 149,804 Operating Lease Liabilities Current portion $ 47,178 $ 45,321 Long-term portion 64,745 100,379 Operating Lease Liabilities Total $ 111,923 $ 145,700

SEGMENT REPORTING, GEOGRAPHIC_2

SEGMENT REPORTING, GEOGRAPHICAL INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
SCHEDULE OF BUSINESS SEGMENTS INFORMATION	SCHEDULE OF BUSINESS SEGMENTS INFORMATION 2024 2023 2024 2023 For the three months ended September 30, For the nine months ended September 30, 2024 2023 2024 2023 Revenue: Vycor Medical $ 372,837 $ 287,559 $ 1,078,644 $ 1,087,758 NovaVision 18,015 21,034 55,454 64,597 Revenue $ 390,852 $ 308,593 $ 1,134,098 $ 1,152,355 Gross Profit Vycor Medical $ 337,404 $ 256,435 $ 973,443 $ 989,288 NovaVision 16,652 19,824 51,690 60,137 Gross Profit $ 354,056 $ 276,259 $ 1,025,133 $ 1,049,425 Operating Income (Loss) Vycor Medical $ 52,688 $ 60,373 $ 223,061 $ 366,360 NovaVision (43,215 ) (41,868 ) (127,783 ) (146,592 ) Corporate (44,608 ) (43,986 ) (123,767 ) (115,521 ) Operating Income (Loss) $ (35,135 ) $ (25,481 ) $ (28,489 ) $ 104,247 September 30, December 31, 2024 2023 Total Assets: Vycor Medical $ 1,028,839 $ 957,936 NovaVision 44,795 33,623 Discontinued operations 970 739 Total Assets $ 1,074,604 $ 992,298
SUMMARY OF GEOGRAPHIC INFORMATION	SUMMARY OF GEOGRAPHIC INFORMATION 2024 2023 2024 2023 For the three months ended September 30, For the nine months ended September 30, 2024 2023 2024 2023 Revenue: United States $ 389,477 $ 306,929 $ 1,131,150 $ 1,147,054 Europe 1,375 1,664 2,948 5,301 Revenue $ 390,852 $ 308,593 $ 1,134,098 $ 1,152,355 Gross Profit United States $ 352,720 $ 274,620 $ 1,022,224 $ 1,044,223 Europe 1,336 1,639 2,909 5,202 Gross Profit $ 354,056 $ 276,259 $ 1,025,133 $ 1,049,425 Operating Income (Loss) United States $ 15,312 $ 24,228 $ 113,166 $ 234,609 Europe (5,839 ) (5,723 ) (17,888 ) (14,841 ) Corporate (44,608 ) (43,986 ) (123,767 ) (115,521 ) Operating Income (Loss) $ (35,135 ) $ (25,481 ) $ (28,489 ) $ 104,247 September 30, December 31, 2024 2023 Total Assets: United States $ 1,064,821 $ 985,718 Europe 8,813 5,841 Discontinued operations 970 739 Total Assets $ 1,074,604 $ 992,298

CONCENTRATION (Tables)

CONCENTRATION (Tables)	9 Months Ended
	Sep. 30, 2024
Risks and Uncertainties [Abstract]
SCHEDULE OF CONCENTRATION	SCHEDULE OF CONCENTRATION Sales Concentration: For the three months For the nine months 2024 2023 2024 2023 Number of customers over 10% 0 1 0 1 Percentage of sales 0 % 16 % 0 % 12 % Accounts Receivable Concentration At September 30, 2024 At December 31, 2023 Number of customers over 10% - - Percentage of accounts receivable - % - %

BASIS OF PRESENTATION (Details

BASIS OF PRESENTATION (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Defined Benefit Plan Disclosure [Line Items]
Net loss	$ 59,817	$ 51,904	$ 100,463	$ (23,364)
Working capital deficit	3,809,459		3,809,459
EuroAmerican Investment Corp [Member]
Defined Benefit Plan Disclosure [Line Items]
Working capital deficiency including term note	300,000		300,000
Accrued interest	508,931		$ 508,931
Maturity date			Mar. 31, 2025
Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Related party liabilities	$ 3,321,298		$ 3,321,298

SCHEDULE OF COMMON STOCK NOT IN

SCHEDULE OF COMMON STOCK NOT INCLUDED IN CALCULATION OF DILUTED NET LOSS PER SHARE (Details) - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	5,124,104	4,894,900
Debentures Convertible into Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	3,852,052	3,622,848
Preferred Shares Convertible into Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	1,272,052	1,272,052

SCHEDULE OF DISCONTINUED OPERAT

SCHEDULE OF DISCONTINUED OPERATIONS (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Current Assets
Cash	$ 970		$ 970		$ 739
Total Current Assets	970		970		739
TOTAL ASSETS	970		970		739
Current Liabilities
Accounts payable	4		4		4
Other current liabilities	(676)		(676)		(1,104)
Total Current Liabilities	(672)		(672)		$ (1,100)
Revenue
Cost of Goods Sold
Gross Profit
Selling, general and administrative	47	425	197	3,365
Total Operating Expenses	(47)	(425)	(197)	(3,365)
Operating Loss	(47)	(425)	(197)	(3,365)
Loss on foreign currency exchange				(152)
Total Other Income (Expense)				(152)
Loss Before Provision for Income Taxes	(47)	(425)	(197)	(3,517)
Provision for income taxes
Loss from discontinued operations, net of tax	$ (47)	$ (425)	$ (197)	$ (3,517)

SUMMARY OF NOTES PAYABLE (Detai

SUMMARY OF NOTES PAYABLE (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Short-Term Debt [Line Items]
Total Notes Payable	$ 337,179	$ 328,267
Total Long term Notes Payable	140,316	142,908
Economic Injury Disaster Loan Program [Member] | CARES Act [Member]
Short-Term Debt [Line Items]
Total Long term Notes Payable	140,316	142,908
Insurance Policy Finance Agreements [Member]
Short-Term Debt [Line Items]
Total Notes Payable	37,179	28,267
EuroAmerican Investment Corp [Member]
Short-Term Debt [Line Items]
Total Notes Payable	300,000	300,000
Peter Zachariou [Member]
Short-Term Debt [Line Items]
Total Related Party Notes Payable	30,000	30,000
Fountainhead Capital Management Limited [Member]
Short-Term Debt [Line Items]
Total Related Party Notes Payable	463,373	463,373
Related Party [Member]
Short-Term Debt [Line Items]
Total Related Party Notes Payable	$ 493,373	$ 493,373

SUMMARY OF NOTES PAYABLE (Det_2

SUMMARY OF NOTES PAYABLE (Details) (Parenthetical) - USD ($)				56 Months Ended
	Jul. 07, 2020	Jun. 25, 2018	Mar. 25, 2011	Nov. 17, 2022
Economic Injury Disaster Loan Program [Member] | CARES Act [Member]
Short-Term Debt [Line Items]
Face amount	$ 150,000
Notes interest rate	3.75%
Debt instrument, term	30 years
Debt instrument periodic payment	$ 731
EuroAmerican Investment Corp [Member]
Short-Term Debt [Line Items]
Face amount			$ 300,000
Notes interest rate			16%
EuroAmerican Investment Corp [Member] | Extended Maturity [Member]
Short-Term Debt [Line Items]
Conversion due date			Mar. 31, 2025
Peter Zachariou [Member]
Short-Term Debt [Line Items]
Face amount		$ 30,000
Notes interest rate		10%
Debt maturity date description		The note was extended for another twelve months on its due date to June 25, 2025 or on demand by the Payee.
Fountainhead Capital Management Limited [Member]
Short-Term Debt [Line Items]
Face amount				$ 463,373
Notes interest rate				10%
Debt maturity date description				The Notes will be due between December 2024 and November 2025 or on demand by the Payee.

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - EuroAmerican Investment Corp [Member] - Amendment Agreement [Member] - USD ($)	9 Months Ended
	Sep. 30, 2024	Jan. 31, 2018
Defined Benefit Plan Disclosure [Line Items]
Other notes payable		$ 300,000
Offering price		$ 0.21
Conversion shares	3,852,052

SCHEDULE OF INVENTORY (Details)

SCHEDULE OF INVENTORY (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials and work in process	$ 79,319	$ 88,236
Finished goods	108,308	145,909
Total Inventory	$ 187,627	$ 234,145

SCHEDULE OF SUPPLEMENTAL BALANC

SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Lease
Operating Lease ROU Assets	$ 115,442	$ 149,804
Current portion	47,178	45,321
Long-term portion	64,745	100,379
Operating Lease Liabilities Total	$ 111,923	$ 145,700

SCHEDULE OF BUSINESS SEGMENTS I

SCHEDULE OF BUSINESS SEGMENTS INFORMATION (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Segment Reporting Information [Line Items]
Revenue	$ 390,852	$ 308,593	$ 1,134,098	$ 1,152,355
Gross Profit	354,056	276,259	1,025,133	1,049,425
Operating Income (Loss)	(35,135)	(25,481)	(28,489)	104,247
Total Assets	1,074,604		1,074,604		$ 992,298
Discontinued Operations [Member]
Segment Reporting Information [Line Items]
Total Assets	970		970		739
Vycor Medical [Member]
Segment Reporting Information [Line Items]
Revenue	372,837	287,559	1,078,644	1,087,758
Gross Profit	337,404	256,435	973,443	989,288
Operating Income (Loss)	52,688	60,373	223,061	366,360
Total Assets	1,028,839		1,028,839		957,936
NovaVision [Member]
Segment Reporting Information [Line Items]
Revenue	18,015	21,034	55,454	64,597
Gross Profit	16,652	19,824	51,690	60,137
Operating Income (Loss)	(43,215)	(41,868)	(127,783)	(146,592)
Total Assets	44,795		44,795		$ 33,623
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Operating Income (Loss)	$ (44,608)	$ (43,986)	$ (123,767)	$ (115,521)

SUMMARY OF GEOGRAPHIC INFORMATI

SUMMARY OF GEOGRAPHIC INFORMATION (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 390,852	$ 308,593	$ 1,134,098	$ 1,152,355
Gross Profit	354,056	276,259	1,025,133	1,049,425
Operating Income (Loss)	(35,135)	(25,481)	(28,489)	104,247
Total Assets	1,074,604		1,074,604		$ 992,298
Discontinued Operations [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Assets	970		970		739
Corporate Segment [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating Income (Loss)	(44,608)	(43,986)	(123,767)	(115,521)
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	389,477	306,929	1,131,150	1,147,054
Gross Profit	352,720	274,620	1,022,224	1,044,223
Operating Income (Loss)	15,312	24,228	113,166	234,609
Total Assets	1,064,821		1,064,821		985,718
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	1,375	1,664	2,948	5,301
Gross Profit	1,336	1,639	2,909	5,202
Operating Income (Loss)	(5,839)	$ (5,723)	(17,888)	$ (14,841)
Total Assets	$ 8,813		$ 8,813		$ 5,841

SEGMENT REPORTING, GEOGRAPHIC_3

SEGMENT REPORTING, GEOGRAPHICAL INFORMATION (Details Narrative)	9 Months Ended
	Sep. 30, 2024 Integer
Business Segments [Member]
Segment Reporting Information [Line Items]
Number of reportable segments	2
Geographic Segments [Member]
Segment Reporting Information [Line Items]
Number of reportable segments	2

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)				3 Months Ended		9 Months Ended
	Aug. 27, 2024	Aug. 16, 2024	Apr. 02, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Nov. 13, 2024	Dec. 31, 2023
Class of Stock [Line Items]
Stock repurchase, value				$ 6,294		$ 6,294
Amortization expense				0	$ 2,363	2,364	$ 7,777
Accrued dividends				$ 162,185	$ 162,185	$ 324,370	$ 324,370
Common stock, shares authorized				55,000,000		55,000,000			55,000,000
Common stock, par value				$ 0.0001		$ 0.0001			$ 0.0001
Preferred stock, shares authorized				10,000,000		10,000,000			10,000,000
Preferred stock, par value				$ 0.0001		$ 0.0001			$ 0.0001
Common stock, shares outstanding				33,372,796		33,372,796			32,628,835
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding				1		1			1
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding				270,306		270,306			270,306
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stock issued during period shares new issues						14,815
Share price				$ 3.75		$ 3.75
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Share price				$ 2.15		$ 2.15
Cumulative preferred dividend rate						12%
Subsequent Event [Member]
Class of Stock [Line Items]
Common stock, shares outstanding								33,372,796
Subsequent Event [Member] | Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding								1
Subsequent Event [Member] | Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding								270,306
Share Purchase Agreement [Member] | Alvaro Pascual-Leone M.D [Member]
Class of Stock [Line Items]
Stock repurchase and cancelled		70,010
Stock repurchase, value		$ 6,294
Financial Advisory and Investment Banking Services Agreement [Member]
Class of Stock [Line Items]
Stock issued during period shares new issues	813,971
Shares issued, value	$ 73,257
Amortization expense				$ 6,105		$ 6,105
Consulting Agreement [Member] | Ricardo Komotar [Member]
Class of Stock [Line Items]
Stock issued during period shares new issues			101,663
Shares issued, value			$ 9,455
Consulting Agreement [Member] | Consultant [Member] | Ricardo Komotar [Member]
Class of Stock [Line Items]
Stock issued during period shares new issues			101,663

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation expense	$ 0	$ 2,363	$ 2,364	$ 7,777
Non Employee Directors [Member] | Directors Deferred Compensation Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation costs	67,152		67,152		$ 2,364
Non-employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation expense	$ 6,105	$ 2,363	$ 8,469	$ 7,777

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative)					3 Months Ended		9 Months Ended
	Oct. 31, 2016 USD ($)	Oct. 31, 2016 EUR (€)	Jun. 30, 2012 USD ($)	Jun. 30, 2012 EUR (€)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Oct. 31, 2016 EUR (€)	Jun. 30, 2012 EUR (€)
Property, Plant and Equipment [Line Items]
Rent expense					$ 20,535	$ 16,362	$ 62,856	$ 53,535
Trade tax reduced	$ 82,000		$ 82,000						€ 75,000	€ 75,000
Interest expenses	$ 13,200	€ 12,000	$ 13,200	€ 12,000
Office Space [Member]
Property, Plant and Equipment [Line Items]
Rent expense							4,300
Other charges							$ 2,700
Lease expire date							Aug. 31, 2023
Lease extended expire date							three years and four months

CONSULTING AND OTHER AGREEMEN_2

CONSULTING AND OTHER AGREEMENTS (Details Narrative) - USD ($)			3 Months Ended		9 Months Ended
	Aug. 27, 2024	Apr. 02, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Share based compensation expense			$ 0	$ 2,363	$ 2,364	$ 7,777
Financial Advisory and Investment Banking Services Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of common stock issued	813,971
Number of common stock issued, value	$ 73,257
Share based compensation expense			$ 6,105		$ 6,105
Consulting Agreement [Member] | Ricardo Komotar [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of common stock issued		101,663
Number of common stock issued, value		$ 9,455

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Related Party Transaction [Line Items]
Preferred stock dividends income	$ 162,185	$ 162,185	$ 324,370	$ 324,370
Accrued dividends, total			2,594,960		$ 2,270,590
Increase decrease in interest payable net	$ 12,571	$ 12,436	37,443	37,080
Fountainhead [Member]
Related Party Transaction [Line Items]
Preferred stock dividends income			226,037	226,037
Accrued dividends, total			1,808,297		1,582,260
Peter Zachariou [Member]
Related Party Transaction [Line Items]
Preferred stock dividends income			83,386	$ 83,386
Accrued dividends, total			$ 667,087		$ 583,701
Directors [Member] | Fountainhead [Member] | Common Stock [Member]
Related Party Transaction [Line Items]
Common stock, ownership percentage	60.90%		60.90%
Directors [Member] | Fountainhead [Member] | Series D Preferred Stock [Member]
Related Party Transaction [Line Items]
Common stock, ownership percentage	69.70%		69.70%
Chairman [Member] | Fountainhead [Member] | Common Stock [Member]
Related Party Transaction [Line Items]
Common stock, ownership percentage	0.15%		0.15%
Chairman [Member] | Fountainhead [Member] | Series D Preferred Stock [Member]
Related Party Transaction [Line Items]
Common stock, ownership percentage	25.70%		25.70%

SCHEDULE OF CONCENTRATION (Deta

SCHEDULE OF CONCENTRATION (Details) - Customer Concentration Risk [Member] - Integer	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Revenue Benchmark [Member]
Concentration Risk [Line Items]
Number of customers over 10%	0	1	0	1
Revenue Benchmark [Member] | Customer [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	0%	16%	0%	12%
Accounts Receivable [Member]
Concentration Risk [Line Items]
Number of customers over 10%
Accounts Receivable [Member] | Customer [Member]
Concentration Risk [Line Items]
Concentration risk, percentage
Accounts Receivable [Member] | Customer [Member] | Maximum [Member]
Concentration Risk [Line Items]
Concentration risk, percentage

CONCENTRATION (Details Narrativ

CONCENTRATION (Details Narrative)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Manufacturer Three [Member] | Purchase [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	10%	10%